It’s been a big two years for biotech investors. But if you ask Po Bronson, a partner at SOSV’s IndieBio, this trend was probably a long time coming. “Often, the implication is that everything must be overpriced,” he tells TechCrunch. “But I think more of it is that some major theses in the markets are […]...